Evidence map›Paper›PMID 34007413›Full record

ArticleBiochemistry (Moscow) Supplement. Series B, Biomedical chemistry2021

Osteogenic and Angiogenic Properties of Heparin as a System for Delivery of Biomolecules for Bone Bioengineering: a Brief Critical Review.

L S Litvinova, K A Yurova, O G Khaziakhmatova, M Yu Khlusova, V V Malashchenko, E O Shunkin, N M Todosenko, I K Norkin, P A Ivanov, I A Khlusov

Open access · bronzeAbstract read
In one paragraph

Article in Biochemistry (Moscow) Supplement. Series B, Biomedical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

L S LitvinovaCenter for Immunology and Cellular Biotechnology of the Immanuel Kant Baltic Federal University, ul. Gaidarа 6, 236041 Kaliningrad, Russia.
K A YurovaCenter for Immunology and Cellular Biotechnology of the Immanuel Kant Baltic Federal University, ul. Gaidarа 6, 236041 Kaliningrad, Russia.
O G KhaziakhmatovaCenter for Immunology and Cellular Biotechnology of the Immanuel Kant Baltic Federal University, ul. Gaidarа 6, 236041 Kaliningrad, Russia.
M Yu KhlusovaDivision of Pathophysiology, Siberian State Medical University, ul. Uchebnaya 39, 634050 Tomsk, Russia.
V V MalashchenkoCenter for Immunology and Cellular Biotechnology of the Immanuel Kant Baltic Federal University, ul. Gaidarа 6, 236041 Kaliningrad, Russia.
E O ShunkinCenter for Immunology and Cellular Biotechnology of the Immanuel Kant Baltic Federal University, ul. Gaidarа 6, 236041 Kaliningrad, Russia.
N M TodosenkoCenter for Immunology and Cellular Biotechnology of the Immanuel Kant Baltic Federal University, ul. Gaidarа 6, 236041 Kaliningrad, Russia.
I K NorkinCenter for Immunology and Cellular Biotechnology of the Immanuel Kant Baltic Federal University, ul. Gaidarа 6, 236041 Kaliningrad, Russia.
P A IvanovCenter for Immunology and Cellular Biotechnology of the Immanuel Kant Baltic Federal University, ul. Gaidarа 6, 236041 Kaliningrad, Russia.
I A KhlusovDepartment of Morphology and General Pathology, Siberian State Medical University, Moskovsky Trakt 2, bldg. 7, 634050 Tomsk, Russia.
Immanuel Kant Baltic Federal University · RUSiberian State Medical University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The review considers complex, controversial, and individual effects of heparin and its derivatives on the bone and circulatory systems in dependence of the dose, the state of the cells and tissues of the recipient. General data on the anticoagulant activity of heparin and its derivatives are presented; special attention is paid to the effect of heparin on mesenchymal cells and tissues and its role in angiogenesis. We also discuss the ability of heparin to bind osteogenic and angiogenic biomolecules in the context of the development of systems for their delivery and sustained controlled release and propose a schematic representation of the positive and side effects of heparin as a delivery system for biomolecules in tissue engineering.

Indexed as

anticoagulantbone tissue bioengineeringdelivery systemhemostasis systemheparinregenerative medicine

Identifiers

PMID34007413
PMCPMC8120488
OpenAlexW3162575456

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.